Loss of Lamivudine Resistance in a Zidovudine and Lamivudine Dual-Resistant HIV-1 Isolate after Discontinuation of In Vitro Lamivudine Drug Pressure
- 1 May 1998
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 3 (4) , 203-207
- https://doi.org/10.1177/135965359800300407
Abstract
We examined the in vitro phenotypic and genotypic profiles of an extensively passaged human immunodeficiency virus type 1 clinical isolate which has been selected for lamivudine resistance, with an M184V mutation in a zidovudine-resistant genetic background, and then cultured with zidovudine alone. Our passaging strategy led to a decrease in lamivudine IC50 values, which were comparable to those prior to lamivudine exposure, and the genotypic restoration of the wild-type sequence at codon 184 of reverse transcriptase.Keywords
This publication has 21 references indexed in Scilit:
- Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced PatientsPublished by American Medical Association (AMA) ,1996
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS, 1996
- Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudineAIDS, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995
- A Randomized Pilot Study of Alternating or Simultaneous Zidovudine and Didanosine Therapy in Patients with Symptomatic Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994
- High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1993
- A Pilot Study of Sequential Therapy with Zidovudine plus Acyclovir, Dideoxyinosine, and Dideoxycytidine in Patients with Severe Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1993
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.Proceedings of the National Academy of Sciences, 1993
- Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gammaAntimicrobial Agents and Chemotherapy, 1992
- (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitroAntimicrobial Agents and Chemotherapy, 1992